Bovie Medical Corporation Announces 510K Submission to the FDA for Its BOSS Soft Tissue Coagulation Device

MELVILLE, N.Y.--(BUSINESS WIRE)--Bovie Medical Corporation (the “Company”) (NYSE-AMEX Symbol: BVX), a manufacturer and marketer of electrosurgical products, today announced a 510K submission to the FDA seeking pre-market clearance for Bovie’s BOSS for surgical applications where soft tissue bipolar coagulation is desired. The BOSS is the latest generation device based on Bovie’s saline enhanced sintered steel technology.
MORE ON THIS TOPIC